<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00245765</url>
  </required_header>
  <id_info>
    <org_study_id>C87040</org_study_id>
    <secondary_id>EudraCT 2005-002141-39</secondary_id>
    <nct_id>NCT00245765</nct_id>
  </id_info>
  <brief_title>Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy</brief_title>
  <official_title>Multicenter, Dose Response, Randomized, Double Blind, Parallel, Placebo Controlled Clinical Trial to Evaluate the Efficacy and the Safety of Subcutaneous CDP870 in Subjects Suffering From Moderate-to-severe Chronic Plaque Psoriasis Who Are Candidates for Systemic Therapy and/or Phototherapy and/or Photochemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <brief_summary>
    <textblock>
      A study to assess the safety and efficacy of 2 different doses of CDP870 versus placebo,
      administered during 12 weeks, to patients suffering from moderate to severe chronic plaque
      psoriasis, extended by a 12 to 24 week follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects achieving PASI75 and rating PGA &quot;clear&quot; or &quot;almost clear&quot; at the end of 12 weeks treatment period</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>to assess the safety and tolerability of the different dose regimens of CDP870 administered subcutaneously for 12 weeks versus placebo</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to assess the efficacy of the different dose regimens of CDP870 administered subcutaneously for 12 weeks versus placebo as measured by:</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the time to onset of action,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the time to relapse after the 12 week treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>period</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the proportion of subjects experiencing rebound</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>during the 2 first months of follow-up</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change from baseline in the body surface area</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(BSA) affected by psoriasis at the end of the 12</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>week treatment period</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the proportion of subjects achieving PASI90 and</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PASI50 at the end of the 12 week treatment period.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the time to discontinuation from treatment period</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>due to lack of efficacy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the PK profile of CDP870 and the apparition of anti</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDP870 antibodies</measure>
  </secondary_outcome>
  <enrollment type="Actual">176</enrollment>
  <condition>Chronic Plaque Psoriasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDP870 (Certolizumab pegol)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  men and women &gt; 18 years;

          -  Chronic plaque psoriasis stable for at least 3 months and moderate to severe for at
             least 6 months;

          -  PASI ≥ 12 and BSA ≥ 10%;

          -  Candidates for systemic psoriasis therapy and/or phototherapy and/or
             photochemotherapy;

        Exclusion Criteria:

          -  Erythrodermic, guttate, palmar or plantar, generalized pustular form of psoriasis;

          -  A history of chronic infection, recent serious or life-threatening infection (within
             six months, including herpes zoster), or any current sign or symptom that may indicate
             an infection (e.g. fever, cough);

          -  White blood cell counts less than 4000/mm3 or more than 20000/mm3;

          -  Suspected or diagnosed demyelinating disease of the central nervous system (e.g.
             multiple sclerosis or optic neuritis);

          -  Systemic Lupus;

          -  Non respect of adequate wash out periods for treatments that might have an impact on
             the disease

          -  Any associated disease that could be impacted by the study treatment intake

          -  Any other condition, which in the Investigator's judgment would make the subject
             unsuitable for inclusion in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>UCB Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nice Cedex 3</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pierre Benite</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint-Etienne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Munster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.ucb.com/_up/ucb_com_patients/documents/C87040_CSS_20080529.pdf</url>
    <description>Clinical Study Summary on UCB.com</description>
  </link>
  <results_reference>
    <citation>Ortonne JP, Tasset C, Reich K. Efficacy of certolizumab pegol, a PEGylated Fab' fragment of an anti-alpha monoclonal antibody, in patients previously exposed to biologicals: preliminary results of a randomised, placebo-controlled, phase II clinical trial in psoriasis. J.Eur.Acad.Dermatol.Venereol. 22[Suppl 1], 2007. Vienna, 16th Congress of the European Academy of Dermatology and Venereology (EADV), May 16-20, 2007.</citation>
  </results_reference>
  <results_reference>
    <citation>Ortonne JP, Sterry W, Tasset C, Reich K. Safety and efficacy of subcutaneous certolizumab pegol, a new anti-TNF-alpha monoclonal antibody, in patients with moderate-to-severe chronic plaque psoriasis: preliminary results from a double-blind, placebo-controlled trial. J.Am.Acad.Dermatol. 56[Suppl 2], AB6. 2007. Washington, DC, 65th Annual Meeting of the American Academy of Dermatology (AAAD), February 2-7, 2007.</citation>
  </results_reference>
  <results_reference>
    <citation>Reich K, Tasset C, Ortonne J. Efficacy and safety of certolizumab pegol, in patients with chronic plaque psoriasis: preliminary results of a randomized, double-blind, placebo-controlled trial. Ann.Rheum.Dis. 66[Suppl 2], 251. 2007. Barcelona, Annual European Congress of Rheumatology EULAR 2007, June 13-16, 2007.</citation>
  </results_reference>
  <results_reference>
    <citation>Ortonne JP, Sterry W, Tasset C, Reich K. Certolizumab pegol, the first pegylated anti-TNF alpha, is effective and well tolerated in patients with moderate-to-severe chronic plaque psoriasis: preliminary data from a phase II study. J.Eur.Acad.Dermatol.Venereol. 21[Suppl 1], 26. 2007. Rhodes, Greece, 15th Congress of the European Academy of Dermatology and Venereology (EADV), October 4-8, 2006.</citation>
  </results_reference>
  <results_reference>
    <citation>Ortonne JP, Sterry W, Coteur G, Keininger DL, Reich K. Improved health-related quality of life in psoriasis patients following 10 weeks' treatment with certolizumab pegol: data from a Phase II study. 2007. Buenos Aires, Argentina, 21st World Congress of Dermatology, October 1-5, 2007.</citation>
  </results_reference>
  <results_reference>
    <citation>Reich K, Sterry W, Tasset C, Terpstra I, Ortonne JP. Efficacy and time to relapse with certolizumab pegol, the first pegylated anti-TNF alpha agent, in patients with moderate-to-severe chronic plaque psoriasis: Phase II study results. 2007. Buenos Aires, Argentina, 21st World Congress of Dermatology, October 1-5, 2007.</citation>
  </results_reference>
  <results_reference>
    <citation>Ortonne JP, Reich K, Sterry W, Terpstra I. Safety and efficacy (PASI 90 and global evaluation) of subcutaneous certolizumab pegol in patients with moderate to severe chronic plaque psoriasis: Results from a double-blind, placebo-controlled trial. J.Am.Acad.Dermatol. 58[Suppl 2], AB4. 2008. San Antonio, 66th Annual Meeting of the American Academy of Dermatology (AAD), February 1-5, 2008.</citation>
  </results_reference>
  <results_reference>
    <citation>Ortonne JP, Reich K, Keininger DL. Certolizumab pegol improved health-related quality of life in patients with psoriasis: Data from a phase II study. J.Am.Acad.Dermatol. 58[Suppl 2], AB121. 2008. San Antonio, 66th Annual Meeting of the American Academy of Dermatology (AAD), February 1-5, 2008.</citation>
  </results_reference>
  <results_reference>
    <citation>Reich K, Ortonne JP, Gottlieb AB, Terpstra IJ, Coteur G, Tasset C, Mease P. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol. 2012 Jul;167(1):180-90. doi: 10.1111/j.1365-2133.2012.10941.x. Epub 2012 Jun 11.</citation>
    <PMID>22413944</PMID>
  </results_reference>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2005</study_first_submitted>
  <study_first_submitted_qc>October 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2005</study_first_posted>
  <last_update_submitted>September 6, 2013</last_update_submitted>
  <last_update_submitted_qc>September 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2013</last_update_posted>
  <keyword>chronic plaque psoriasis, anti TNFα</keyword>
  <keyword>CDP870, Cimzia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Certolizumab Pegol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

